Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23-Reference-Cited by-同舟云学术

Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23

Published:2023-02-02 Issue:5 Volume:28 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Skowronski Danuta M¹²,Chuang Erica SY²,Sabaiduc Suzana²,Kaweski Samantha E²,Kim Shinhye²,Dickinson James A³,Olsha Romy⁴,Gubbay Jonathan B⁵⁴,Zelyas Nathan⁶,Charest Hugues⁷,Bastien Nathalie⁸,Jassem Agatha N¹²,De Serres Gaston⁹¹⁰⁷

Affiliation:

1. University of British Columbia, Vancouver, Canada

2. British Columbia Centre for Disease Control, Vancouver, Canada

3. University of Calgary, Calgary, Canada

4. Public Health Ontario, Toronto, Canada

5. University of Toronto, Toronto, Canada

6. Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Canada

7. Institut National de Santé Publique du Québec, Québec, Canada

8. National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada

9. Centre Hospitalier Universitaire de Québec, Québec, Canada

10. Laval University, Quebec, Canada

Abstract

The Canadian Sentinel Practitioner Surveillance Network estimated vaccine effectiveness (VE) during the unusually early 2022/23 influenza A(H3N2) epidemic. Like vaccine, circulating viruses were clade 3C.2a1b.2a.2, but with genetic diversity affecting haemagglutinin positions 135 and 156, and reassortment such that H156 viruses acquired neuraminidase from clade 3C.2a1b.1a. Vaccine provided substantial protection with A(H3N2) VE of 54% (95% CI: 38 to 66) overall. VE was similar against H156 and vaccine-like S156 viruses, but with potential variation based on diversity at position 135.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference33 articles.

1. Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada.;Kim;Euro Surveill,2022

2. National influenza annual report, Canada, 2021-2022: A brief, late influenza epidemic.;Buckrell;Can Commun Dis Rep,2022

3. Public Health Agency of Canada (PHAC). FluWatch report: January 8 to January 14, 2023 (week 2). Ottawa: PHAC

4. 2023. [Accessed: 31 Jan 2023). Available from: https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance/weekly-reports-2022-2023-season.html

5. National influenza mid-season report, 2022-2023: A rapid and early epidemic onset.;Ben Moussa;Can Commun Dis Rep,2023

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influenza vaccine effectiveness against influenza-associated hospitalizations in children, Hong Kong, November 2023 to June 2024;2024-08-30

2. Wastewater Surveillance to Confirm Differences in Influenza A Infection between Michigan, USA, and Ontario, Canada, September 2022–March 2023;Emerging Infectious Diseases;2024-08

3. Changes in the etiological structure of severe acute respiratory viral infections in children and adults under the influence of the COVID-19 pandemic;Journal of microbiology, epidemiology and immunobiology;2024-07-16

4. Late‐Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022–April 2023;Influenza and Other Respiratory Viruses;2024-06

5. Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022–23 VEBIS multicentre study in Europe;Vaccine;2024-06